This is the fifth competing renewal of the Cancer Center Support Grant (CCSG) at Vanderbilt-Ingram Cancer Center (VICC). VICC is a matrix center within Vanderbilt University Medical Center and Vanderbilt University that integrates the cancer-related expertise and resources of the Schools of Medicine, Nursing, Arts and Sciences and Engineering, the Peabody School of Education and the fully integrated Veterans Administration Medical Center. The major clinical facilities and the majority of research facilities are located on one campus, which promotes informal interactions, sharing of resources and productive collaborations. Established in 1993, VICC functions as an organizational unit with a supra-departmental status. VICC-specific responsibilities and aims are 1) to conduct, support and enhance state-of-the-art, multidisciplinary basic, clinical and population- based research; 2) to coordinate and integrate cancer-related activities across Vanderbilt and to collaborate with our local, regional, national and global partners; 3) to train and develop the next generation of cancer investigators, cancer leaders and the continuum of cancer care providers; and 4) to assess and prioritize community needs and to leverage partnerships to address those needs through cancer research, care and control activities. The research, training, and community outreach and engagement objectives are accomplished through CCSG and institutionally supported organizational capabilities, planning and evaluation, and eight research programs. The VICC Research Programs are Signal Transduction and Cell Proliferation, Genome Maintenance, Host-Tumor Interactions, Gastrointestinal Cancer, Translational Research and Interventional Oncology, Breast Cancer, Cancer Epidemiology, and Cancer Health Outcomes and Control. Eleven shared resources are proposed, all previously supported. Remarkable VICC growth and scientific discovery over the past project period has led to 22 new multi-investigator grants for a total of 71, and 8 new training grants for a total of 26. In addition, two NCI SPOREs were successfully renewed. With these and many other NCI grants, peer-reviewed funding increased 35%. Significant accomplishments have been made in precision oncology, cancer epidemiology, health outcomes and control, genomics, cancer drug discovery, early detection and prevention, and cancer disparities research. Increased VICC space and facilities, along with philanthropic and institutional funds, supported the recruitment of 67 new faculty, who join a dedicated team carrying out the VICC mission: to alleviate cancer death and suffering through pioneering research; innovative patient-centered care; and evidence-based prevention, education and community initiatives. VICC senior leadership provides effective oversight and catalyzes innovative and paradigm-shifting science that translates to benefit for our patients and the community we serve in our catchment and reduces the burden of cancer nationally and globally.

Public Health Relevance

Vanderbilt-Ingram Cancer Center (VICC) is a matrix center that integrates all of Vanderbilt?s cancer-related expertise and resources in order to deliver its mission of alleviating cancer death and suffering through pioneering research; innovative patient-centered care; and evidence-based prevention, education and community initiatives. This mission is accomplished through translation of exceptional cancer research into interventions for the prevention, diagnosis and treatment of cancer. The Cancer Center Support Grant provides infrastructure to facilitate multidisciplinary basic, clinical and population-based research, to advance VICC discoveries to cancer patients and the community, and to educate and train the next generation of cancer investigators and workforce.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA068485-25
Application #
10024630
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Roberson, Sonya
Project Start
1998-09-01
Project End
2025-08-31
Budget Start
2020-09-15
Budget End
2021-08-31
Support Year
25
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Type
DUNS #
079917897
City
Nashville
State
TN
Country
United States
Zip Code
37232
Pannala, Venkat R; Wall, Martha L; Estes, Shanea K et al. (2018) Metabolic network-based predictions of toxicant-induced metabolite changes in the laboratory rat. Sci Rep 8:11678
Zhao, Shilin; Li, Chung-I; Guo, Yan et al. (2018) RnaSeqSampleSize: real data based sample size estimation for RNA sequencing. BMC Bioinformatics 19:191
Croessmann, Sarah; Sheehan, Jonathan H; Lee, Kyung-Min et al. (2018) PIK3CA C2 Domain Deletions Hyperactivate Phosphoinositide 3-kinase (PI3K), Generate Oncogene Dependence, and Are Exquisitely Sensitive to PI3K? Inhibitors. Clin Cancer Res 24:1426-1435
Doxie, Deon B; Greenplate, Allison R; Gandelman, Jocelyn S et al. (2018) BRAF and MEK inhibitor therapy eliminates Nestin-expressing melanoma cells in human tumors. Pigment Cell Melanoma Res 31:708-719
Salisbury-Ruf, Christi T; Bertram, Clinton C; Vergeade, Aurelia et al. (2018) Bid maintains mitochondrial cristae structure and function and protects against cardiac disease in an integrative genomics study. Elife 7:
Laroumanie, Fanny; Korneva, Arina; Bersi, Matthew R et al. (2018) LNK deficiency promotes acute aortic dissection and rupture. JCI Insight 3:
Burns, Michael C; Howes, Jennifer E; Sun, Qi et al. (2018) High-throughput screening identifies small molecules that bind to the RAS:SOS:RAS complex and perturb RAS signaling. Anal Biochem 548:44-52
Phelps, Hannah M; Al-Jadiry, Mazin F; Corbitt, Natasha M et al. (2018) Molecular and epidemiologic characterization of Wilms tumor from Baghdad, Iraq. World J Pediatr 14:585-593
Liu, Qi; Herring, Charles A; Sheng, Quanhu et al. (2018) Quantitative assessment of cell population diversity in single-cell landscapes. PLoS Biol 16:e2006687
Almodovar, Karinna; Iams, Wade T; Meador, Catherine B et al. (2018) Longitudinal Cell-Free DNA Analysis in Patients with Small Cell Lung Cancer Reveals Dynamic Insights into Treatment Efficacy and Disease Relapse. J Thorac Oncol 13:112-123

Showing the most recent 10 out of 2462 publications